Reporting owner · CIK 0001134655
Gadicke Ansbert
Visual SEC Form 4 history across 2 companies, 13 transactions and 3 filings.
10%Entrada Therapeutics, Inc.
Open-market mix
14%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Jan 26
$20M
Aug 26
−$1.1M
Transaction texture
Ownership and ticket size
Average P/S size$3M
Median P/S size$200K
Direct0
Indirect13
Aug 31, 2026sale
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
sale at Entrada Therapeutics, Inc. on Aug 31, 2026 valued at $309,370.
Review SEC filingAssociated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| TRDA | GADICKE ANSBERT | 10% | sale | 44.2k | -$30.9M | S | 0.0% | 08/31 | 08/31 | |
| TRDA | GADICKE ANSBERT | 10% | sale | 3.73k | -$2.61M | S | 0.0% | 08/31 | 08/28 | |
| TRDA | GADICKE ANSBERT | 10% | sale | 38.9k | -$28.0M | S | 0.0% | 08/31 | 08/27 | |
| TRDA | GADICKE ANSBERT | 10% | sale | 14.5k | -$10.2M | S | — | 08/27 | 08/26 | |
| TRDA | GADICKE ANSBERT | 10% | sale | 26.5k | -$19.9M | S | — | 08/27 | 08/25 | |
| TRDA | GADICKE ANSBERT | 10% | sale | 21.6k | -$15.8M | S | — | 08/27 | 08/24 | |
| AKTS | GADICKE ANSBERT | 10% | C | 6.00M | $0 | C | — | 01/14 | 01/12 | |
| AKTS | GADICKE ANSBERT | 10% | C | 22.5M | $0 | C | — | 01/14 | 01/12 | |
| AKTS | GADICKE ANSBERT | 10% | C | 5.00M | $0 | C | — | 01/14 | 01/12 | |
| AKTS | GADICKE ANSBERT | 10% | buy | 1.11M | $2.00B | P | — | 01/14 | 01/12 |
Gadicke Ansbert Insider Activity FAQ
SEC Form 4 context
Who is Gadicke Ansbert?
Gadicke Ansbert is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001134655.
Which companies has Gadicke Ansbert reported transactions for?
Entrada Therapeutics, Inc., Aktis Oncology, Inc.
When was Gadicke Ansbert's latest insider buy?
buy at Aktis Oncology, Inc. on Jan 12, 2026 valued at $20,029,986.
When was Gadicke Ansbert's latest insider sale?
sale at Entrada Therapeutics, Inc. on Aug 31, 2026 valued at $309,370.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.